| scholarly article | Q13442814 |
| review article | Q7318358 |
| P356 | DOI | 10.1517/14712598.5.5.663 |
| P698 | PubMed publication ID | 15934841 |
| P2093 | author name string | Keiya Ozawa | |
| Imaharu Nakano | |||
| Shin-ichi Muramatsu | |||
| Hideo Tsukada | |||
| P2860 | cites work | Hereditary progressive dystonia with marked diurnal fluctuation caused by mutations in the GTP cyclohydrolase I gene | Q24314922 |
| GDNF: a glial cell line-derived neurotrophic factor for midbrain dopaminergic neurons | Q24336322 | ||
| Neuroprotection in a rat Parkinson model by GDNF gene therapy using EIAV vector | Q40568114 | ||
| The potential of GDNF as a treatment for Parkinson's disease | Q40603600 | ||
| AAV serotype 2 vectors preferentially integrate into active genes in mice | Q40643545 | ||
| Glial cell line-derived neurotrophic factor (GDNF) gene delivery protects dopaminergic terminals from degeneration | Q40811477 | ||
| Triple transduction with adeno-associated virus vectors expressing tyrosine hydroxylase, aromatic-L-amino-acid decarboxylase, and GTP cyclohydrolase I for gene therapy of Parkinson's disease | Q40861090 | ||
| Convection-enhanced delivery of AAV vector in parkinsonian monkeys; in vivo detection of gene expression and restoration of dopaminergic function using pro-drug approach | Q40870377 | ||
| Differential effects of glial cell line-derived neurotrophic factor (GDNF) in the striatum and substantia nigra of the aged Parkinsonian rat. | Q40905804 | ||
| Recombinant adeno-associated viral vector-mediated glial cell line-derived neurotrophic factor gene transfer protects nigral dopamine neurons after onset of progressive degeneration in a rat model of Parkinson's disease | Q40906891 | ||
| Clinicopathological findings following intraventricular glial-derived neurotrophic factor treatment in a patient with Parkinson's disease | Q40929764 | ||
| GDNF: a novel factor with therapeutic potential for neurodegenerative disorders | Q40954976 | ||
| Behavioral and cellular protection of rat dopaminergic neurons by an adenoviral vector encoding glial cell line-derived neurotrophic factor. | Q40983409 | ||
| Dopaminergic neurons protected from degeneration by GDNF gene therapy | Q41128316 | ||
| Nucleotide sequencing and generation of an infectious clone of adeno-associated virus 3. | Q41190212 | ||
| Long-term gene expression and phenotypic correction using adeno-associated virus vectors in the mammalian brain | Q42280576 | ||
| Long-term restoration of striatal L-aromatic amino acid decarboxylase activity using recombinant adeno-associated viral vector gene transfer in a rodent model of Parkinson's disease | Q43535625 | ||
| Functional effect of adeno-associated virus mediated gene transfer of aromatic L-amino acid decarboxylase into the striatum of 6-OHDA-lesioned rats. | Q43707952 | ||
| Long-term pharmacologically regulated expression of erythropoietin in primates following AAV-mediated gene transfer. | Q43727676 | ||
| Behavioral recovery in a primate model of Parkinson's disease by triple transduction of striatal cells with adeno-associated viral vectors expressing dopamine-synthesizing enzymes | Q43892747 | ||
| Recombinant AAV viral vectors pseudotyped with viral capsids from serotypes 1, 2, and 5 display differential efficiency and cell tropism after delivery to different regions of the central nervous system | Q45007196 | ||
| Involvement of sensorimotor, limbic, and associative basal ganglia domains in L-3,4-dihydroxyphenylalanine-induced dyskinesia. | Q45281153 | ||
| Chromosomal effects of adeno-associated virus vector integration | Q45734034 | ||
| Adeno-associated virus (AAV)-3-based vectors transduce haematopoietic cells not susceptible to transduction with AAV-2-based vectors | Q45741486 | ||
| Recombinant AAV serotype 1 transduction efficiency and tropism in the murine brain | Q45864411 | ||
| Uneven pattern of dopamine loss in the striatum of patients with idiopathic Parkinson's disease. Pathophysiologic and clinical implications | Q48088787 | ||
| Quantification of mRNA of tyrosine hydroxylase and aromatic L-amino acid decarboxylase in the substantia nigra in Parkinson's disease and schizophrenia | Q48226960 | ||
| Effect of 6R-L-erythro-5,6,7,8-tetrahydrobiopterin and infusion of L-tyrosine on the in vivo L-[beta-11C] DOPA disposition in the monkey brain | Q49052333 | ||
| A comparison of 11C-labeled L-DOPA and L-fluorodopa as positron emission tomography tracers for the presynaptic dopaminergic system | Q50108778 | ||
| In vivo PET imaging of gene expression in Parkinsonian monkeys. | Q53636491 | ||
| Efficient delivery of Cre-recombinase to neurons in vivo and stable transduction of neurons using adeno-associated and lentiviral vectors | Q24797018 | ||
| Direct brain infusion of glial cell line-derived neurotrophic factor in Parkinson disease | Q28187904 | ||
| Reversal of motor impairments in parkinsonian rats by continuous intrastriatal delivery of L-dopa using rAAV-mediated gene transfer | Q31045537 | ||
| Delivery of a GDNF gene into the substantia nigra after a progressive 6-OHDA lesion maintains functional nigrostriatal connections | Q31457974 | ||
| Antiparkinsonian and behavioral effects of inactivation of the substantia nigra pars reticulata in hemiparkinsonian primates | Q31848481 | ||
| Genetic fate of recombinant adeno-associated virus vector genomes in muscle | Q33186207 | ||
| Molecular biology of catecholamine-related enzymes in relation to Parkinson's disease. | Q33541804 | ||
| Midbrain injection of recombinant adeno-associated virus encoding rat glial cell line-derived neurotrophic factor protects nigral neurons in a progressive 6-hydroxydopamine-induced degeneration model of Parkinson's disease in rats | Q33745707 | ||
| An AAV-derived Apaf-1 dominant negative inhibitor prevents MPTP toxicity as antiapoptotic gene therapy for Parkinson's disease | Q33943954 | ||
| Exogenous control of mammalian gene expression through modulation of RNA self-cleavage | Q33981633 | ||
| Modeling Parkinson's disease in rats: an evaluation of 6-OHDA lesions of the nigrostriatal pathway | Q34133059 | ||
| Circulating anti-wild-type adeno-associated virus type 2 (AAV2) antibodies inhibit recombinant AAV2 (rAAV2)-mediated, but not rAAV5-mediated, gene transfer in the brain | Q34193457 | ||
| Clades of Adeno-associated viruses are widely disseminated in human tissues. | Q34193756 | ||
| L-DOPA and psychosis: evidence for L-DOPA-induced increases in prefrontal cortex dopamine and in serum corticosterone | Q34370834 | ||
| Reversal of dyskinesias in an animal model of Parkinson's disease by continuous L-DOPA delivery using rAAV vectors | Q34385896 | ||
| Functional imaging studies on dopamine and motor control | Q34478871 | ||
| Lidocaine and muscimol microinjections in subthalamic nucleus reverse Parkinsonian symptoms | Q34517896 | ||
| Duodenal levodopa infusion monotherapy vs oral polypharmacy in advanced Parkinson disease | Q34554465 | ||
| The effects of central aromatic amino acid DOPA decarboxylase inhibition on the motor actions of L-DOPA and dopamine agonists in MPTP-treated primates | Q35042094 | ||
| Safety of adeno-associated virus gene therapy vectors: a current evaluation | Q35194547 | ||
| Adeno-associated viral vectors for Parkinson's disease | Q35216667 | ||
| The subthalamic nucleus in the context of movement disorders | Q35579828 | ||
| The antiprogestin-dependent GeneSwitch system for regulated gene therapy | Q35605083 | ||
| Evaluation of risks related to the use of adeno-associated virus-based vectors. | Q35610576 | ||
| Long-term doxycycline-controlled expression of human tyrosine hydroxylase after direct adenovirus-mediated gene transfer to a rat model of Parkinson's disease. | Q35734505 | ||
| PINK, PANK, or PARK? A clinicians' guide to familial parkinsonism | Q35920094 | ||
| Integration of adeno-associated virus (AAV) and recombinant AAV vectors | Q35965997 | ||
| The role of radiotracer imaging in Parkinson disease | Q36019158 | ||
| Schizophrenia is associated with elevated amphetamine-induced synaptic dopamine concentrations: evidence from a novel positron emission tomography method | Q36050571 | ||
| Intrastriatal injection of an adenoviral vector expressing glial-cell-line-derived neurotrophic factor prevents dopaminergic neuron degeneration and behavioral impairment in a rat model of Parkinson disease. | Q36561684 | ||
| Lentiviral vector delivery of parkin prevents dopaminergic degeneration in an alpha-synuclein rat model of Parkinson's disease | Q37713838 | ||
| Human positron emission tomographic [18F]fluorodopa studies correlate with dopamine cell counts and levels | Q39113010 | ||
| Correlation of striatal fluorodopa uptake in the MPTP monkey with dopaminergic indices | Q39113016 | ||
| Continuous low-level glial cell line-derived neurotrophic factor delivery using recombinant adeno-associated viral vectors provides neuroprotection and induces behavioral recovery in a primate model of Parkinson's disease. | Q40464992 | ||
| Second-generation tetracycline-regulatable promoter: repositioned tet operator elements optimize transactivator synergy while shorter minimal promoter offers tight basal leakiness | Q40537918 | ||
| P433 | issue | 5 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | Parkinson's disease | Q11085 |
| gene therapy | Q213901 | ||
| vector-borne disease | Q2083837 | ||
| P304 | page(s) | 663-671 | |
| P577 | publication date | 2005-05-01 | |
| P1433 | published in | Expert Opinion on Biological Therapy | Q5421201 |
| P1476 | title | Gene therapy for Parkinson's disease using recombinant adeno-associated viral vectors | |
| P478 | volume | 5 |
| Q34209755 | A phase I study of aromatic L-amino acid decarboxylase gene therapy for Parkinson's disease |
| Q39306233 | Atlas-based functional radiosurgery: early results |
| Q36418370 | Gene therapeutics for periodontal regenerative medicine. |
| Q41830129 | Gene therapy in periodontics |
| Q37140794 | Progress in transduction of cerebellar Purkinje cells in vivo using viral vectors |
Search more.